David Albert

Is AI hype or reality in nuclear medicine? That question was addressed in point-counterpoint articles in AJR that highlight the progress -- and challenges -- facing AI adoption in the discipline. Read more at https://buff.ly/4aO7VIU #radiology #medicalimaging #nuclearmedicine #AI #ImagingAI

4

#AIinSurgery innovates cardiac surgical decision support: #AATS2024 Poster highlights #ChatGPT potential as an AI tool for less-complex cases, offering quick insights from vast patient data. See our other presentations and posters.

9

The landscape of seizure monitoring is changing and we’re glad to be a part of it! See what Medical Device Network has to say about our latest FDA clearances for REMI Remote EEG Monitoring System and REMI Vigilenz AI For event detection. https://lnkd.in/eKSyszca #EEG #wearabletech #seizuredetection #seizure #seizuremonitoring

41

Capstan Medical, a Santa Cruz, CA-based developer of robotic-enabled minimally invasive solutions to address heart valve disease, raised $110M in Series C funding. The round was led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures and new investment from Gideon Strategic Partners. https://lnkd.in/dnVaBPVm

1

SignalHF*, Implicity's new AI algorithm, revolutionizes heart failure care with its predictive capability. *SignalHF is an FDA-cleared Class II medical device. See the instructions for use for more information. #SignalHF #HeartFailurePrediction #HealthTech #PredictiveAnalytics #HealthcareInnovation #MedicalInnovation #cardiology #heartfailure

17

The #SMARTtrial 1-year outcomes presented at #ACC2024 show fundamental design differences in #TAVR devices can impact valve performance. Explore the evidence. https://bit.ly/4bjE62N Risk info: https://bit.ly/4bkMTkW

16

Accelerating Surgical Device Adoption: AI-Powered 5D XR for Scalable Training and Faster Revenue Growth Scaling surgical device training has always been challenging—balancing the logistics of in-person sessions, the costs of extensive travel, and the limitations of standard e-learning platforms. The future demands a better solution, and now it’s here. Imagine training surgeons on your latest devices in a fully immersive, real-time environment that mimics the precision and dynamics of the operating room—without the need for travel. Our AI-powered 5D XR platform delivers just that. This isn’t an enhanced simulation or VR—it’s a revolutionary leap forward that replicates the complexity of real-world surgical cases through dynamic digital twins and advanced AI, providing hands-on mastery like never before. For surgical device companies, the impact is clear: - Internal Teams: Accelerate the expertise of your internal teams, giving them the tools to fully understand and train others on your devices with real-time, immersive learning. - Surgeons and End-Users: Seamlessly onboard surgeons to proficiency with real-time feedback and case-based training, enabling them to perform confidently after mastering just 20 cases—without leaving their local hospital. - Global Scale, Zero Travel: Deliver consistent, high-impact training to anyone, anywhere. Surgeons, proctors, and technicians can all engage in the training process, overcoming geographical barriers and eliminating costly travel. Your surgeons won’t be practicing on VR simulations or pre-recorded videos. They’ll be fully immersed in real-time cases, gaining skills that replicate the use of your devices in actual surgeries—achieving proficiency faster and more effectively than ever before. Welcome to the next era of surgical training. Let’s make your devices the most advanced, best understood, and best adopted. #AIinHealthcare #5DXR #SurgicalTraining #MedicalDeviceInnovation

12

New in CARJ: Patient Perspectives of Artificial Intelligence in Medical Imaging 🚀 Radiology is poised for AI integration, but an important aspect remains under-explored: patient perspectives. The literature has highlighted 3 main patient concerns: performance, accountability, and understanding. Read more here: https://bit.ly/3O6qZIT #AI #Radiology #HealthcareInnovation

10

2 Comments

Great article from Cardiovascular Business spotlighting our monumental FDA clearance of the game changing Kardia 12L ECG System, powered by the revolutionary KAI 12L AI algorithm. As our CEO Priya Abani said, "It's the first FDA-cleared AI to detect a heart attack on a reduced lead set, and returns results for our widest range of conditions ever." Read the full article below to learn more. #AI #ECG #HealthTech #DigitalHealth #AliveCor #HeartHealth

125

5 Comments

This hybrid #quantum framework enhances #lung cancer detection by improving the accuracy and speed of tumour classification from CT and X-ray images. Its integration into clinical practice could lead to earlier #diagnoses and better patient outcomes, though it may not be suitable for all cancer types.

4

🚀 Exciting News! 🚀 MediCardia Health Inc. and Wearable Technologies Inc. announce Multi-Year Agreement to Enhance Cardiology Care with Advanced AI Integration   MediCardia, a leading provider of comprehensive Cardiology care management and remote patient monitoring (RPM) solutions, today announced a multi-year agreement with Wear-Tech, a pioneer in wearable health technology and AI-driven safety and healthcare solutions. This strategic partnership will focus on integrating Wear-Tech's AI Assistant, MAHI, into MediCardia's first-of-its-kind smart digital medicine and connected health platform. Under this partnership, Wear-Tech will support the maintenance and development of MediCardia's next-generation platform, enhancing its capabilities with MAHI's features. This collaboration aims to revolutionize Cardiology care through the integration of a scalable intelligence module that optimizes efficiency and drives quality to maximize patient outcomes, leveraging remote monitoring and virtual care. "At MediCardia, our mission is to provide superior Cardiology care through innovative technology. Partnering with Wear-Tech to integrate MAHI into our platform aligns perfectly with our goals," said Dr. Indrajit Choudhuri, CEO of MediCardia Health Inc. "This collaboration will empower healthcare providers with sophisticated tools to deliver better patient outcomes." MediCardia Health Inc.: Comprehensive Care Management: MediCardia's platform offers a robust suite of tools for chronic care management (CCM), enabling seamless coordination between healthcare providers and patients. Remote Patient Monitoring: The RPM solutions by MediCardia provide real-time data collection and analysis, ensuring timely interventions and personalized care plans. Data-Driven Insights: Leveraging extensive clinical data, MediCardia enhances decision-making processes and improves patient outcomes through actionable insights. MAHI Experience: Advanced AI Capabilities: MAHI, Wear-Tech's AI Assistant, utilizes cutting-edge machine learning algorithms and small language models to deliver precise and predictive healthcare solutions. Wearable Integration: Wear-Tech's innovative wearable devices offer continuous monitoring and data collection, providing a comprehensive health overview for patients and providers. Enhanced Patient Engagement: MAHI's user-friendly interface and intelligent features foster improved patient engagement, experience, and adherence to treatment plans. The Future of Cardiology Care The integration of MAHI into MediCardia's platform will bring several transformative benefits, including: - Improved Diagnostic Accuracy - Streamlined Care Coordination - Personalized Treatment Plans "We are thrilled to partner with MediCardia to bring our AI technology to their already impressive platform," said Wear-Tech CEO Deepak Arora, MBA. "Together, we will push the boundaries of what's possible in Cardiology care, making it more proactive, personalized, and efficient."

32

14 Comments

How are innovations in medical technology, evolving regulations, and market competition reshaping the future of healthcare? Read through this week's #MedtechNews roundup to see the latest updates in the industry. Masimo's FDA clearance sets the stage for competition with Owlet Baby Care in the baby pulse oximetry OTC market. Owlet, having cleared its Dream Sock monitor, entered the market recently, while Masimo, with its Stork device, now aims to penetrate the OTC sector. Despite Owlet's past regulatory challenges, Masimo's entry intensifies competition, with analysts foreseeing significant opportunities in the baby monitoring sector. Masimo plans to launch OTC Stork bundles with enhanced features this summer while also considering restructuring amid a proxy challenge from Politan Capital. https://lnkd.in/gU5U6kXh The FDA's final rule on laboratory-developed tests (LDTs) represents a significant regulatory shift akin to medical devices. Over the next four years, the FDA plans to phase out its less-stringent approach, citing the increasing complexity and risks of LDTs. Despite lab concerns, the FDA asserts that enhanced oversight will foster innovation while ensuring accurate results, with exemptions for existing and unmet LDTs, though their impact remains debated. https://lnkd.in/gKJQKb99 GE HealthCare introduced its Signa Magnus head-only magnetic resonance (MR) scanner tailored for neuroscience applications, currently pending FDA 510(k) clearance. Addressing the limitations of conventional whole-body MR systems, the scanner aims to advance neuroscience research by enabling enhanced diagnostics of neurological disorders. GE's most advanced 3.0T MR imaging technology, including HyperG gradient technology, equips Signa Magnus to enable previously unattainable detailed imaging. GE HealthCare emphasises the system's potential to push boundaries in neuro-MR research, offering deep-learning algorithms to amplify capabilities while also providing an upgrade path for existing 3.0T systems to Signa Magnus. https://lnkd.in/gN5r-BWb Inspire Medical Systems shares plummeted 16% to $206 in after-hours trading today, despite surpassing Wall Street's expectations for the first quarter. The Minneapolis-based company, specialising in neuromodulation technology for sleep apnea treatment, reported a $10 million loss, equivalent to 65¢ per share, on $164 million in sales for the quarter ending March 31, 2024. Inspire attributed its revenue growth, which exceeded the Wall Street consensus, to increased market penetration, expansion into new territories, and heightened awareness of its therapy among physicians and patients, prompting the company to raise its revenue guidance for 2024 to $783 million to $793 million. https://lnkd.in/gEt9v3vF

8

1 Comment

Serial acquisitions of anesthesia practices led to price increases of 30 percent with no quality improvements, from Aslihan Asil, Paulo Ramos, Amanda Starc, and Thomas G. Wollmann https://lnkd.in/eW4kpmiU

5